Cefepime + VNRX-5133

Unassigned

New Medicines

Complicated urinary tract infection

Information

New formulation
VenatoRx
VenatoRx

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

VNRX-5133 is a beta-lactamase inhibitor
The population eligible to receive this difficult to estimate and may vary according to local resistance patterns. In 2017 and 18 there were around150000 hospital admissions for cUTIs mostly due to gram negative bacteria. Assuming 15% of these infections are resistant to currently available antibiotics, 22500 adults may be eligible for antibiotics reserved for resistant gram negative infections. [2]
Complicated urinary tract infection
Intravenous